NCT00218049

Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals

Phase 1, Double-blind, Placebo-controlled Assessment of Interactions Between 2 Doses of Cocaine and Three Doses of Escalating Vanoxerine (GBR 12909) in Cocaine Using Volunteers

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: National Institute on Drug Abuse (NIDA) · NIH
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Cocaine dependence is a major public health problem; an effective primary treatment for cocaine dependent individuals has yet to be found. The purpose of this study is to determine the safety and effects of vanoxerine (GBR 12909) in treating cocaine dependent individuals.

Detailed description

Cocaine is a strong central nervous system stimulant that is widely abused throughout the United Sates. Due to its widespread use, it is important to develop an effective treatment for cocaine dependence. Dopamine transporters (DAT) play an important role in the addictive nature of cocaine; the use of compounds that target DAT may be effective in treating cocaine dependent individuals. Research shows that GBR 12909 has a strong affinity for DAT. The purpose of this study is to determine the safety and potential interaction of GBR 12909 and cocaine in cocaine dependent individuals.

Conditions

• Cocaine Abuse
• Cocaine-Related Disorders

Interventions

Type	Name	Description
DRUG	GBR 12909	50mg GBR 12909 over 12 days
DRUG	GBR 12909	GBR 12909 75 mg over 12 day period
DRUG	GBR 12909	GBR 12909 100 mg over 12 day period

Timeline

• Start date: 2004-12-01
• Primary completion: 2005-07-01
• Completion: 2005-07-01
• First posted: 2005-09-22
• Last updated: 2017-01-12

Locations

1 site across 1 country: United States